An uncontrolled, open label study of XXXX in severe alopecia areata.

@entity1 @entity3378 @entity792 @entity1663
BACKGROUND: @entity1663 ( @entity1663 ) is an @entity792 mediated by T lymphocytes. Many treatments have been used but their results remain disappointing. There is a need to propose new therapeutic alternatives. METHODS: During a period of 3 years, 26 @entity1 with recalcitrant or severe @entity1663 (>40% hair loss) were enrolled in an open-label uncontrolled clinical trial. According to the response to @entity3378 , @entity1 were grouped into 3 categories: no hair regrowth (< 10% terminal hair), partial hair regrowth (10%-90% terminal hair), and complete hair regrowth (90%-100% terminal hair). Efficacy evaluation was performed with clinical examination. RESULTS: Twenty-two @entity1 completed the treatment. Overall, 68.2% (15 of 22 @entity1 ) responded to therapy: 27.3% (6 of 22 @entity1 ) achieved complete hair regrowth, and 40.9% had partial hair regrowth. Seven (31.8%) @entity1 had no hair regrowth. Of the 22 @entity1 with complete and partial remission, 10 (45.5%) suffered a partial or complete relapse. Side effects following treatment were seen in 7 (31.8%) @entity1 . CONCLUSION: @entity3378 could be considered as a therapeutic alternative in the treatment of @entity1663 , because of its safety profile, cosmetically acceptable efficacy, and good tolerability.
